Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A female renal transplant recipient is evaluated in the ambulatory care center for a persistent cough, low-grade fever, and purulent sputum production. She has been clinically stable on a maintenance immunosuppressive regimen of tacrolimus, mycophenolate mofetil, and prednisone for the past three years. Her most recent renal function and drug trough levels from two weeks ago were within target ranges. A chest radiograph reveals a new focal infiltrate in the right lower lobe, and the physician decides to prescribe a 7-day course of oral clarithromycin for atypical bacterial coverage. In addition to treating the respiratory infection, which of the following are the most appropriate immediate steps in monitoring and treatment evaluation for this patient? (Select exactly two options)

  1. Empirically reduce the daily dosage of tacrolimusAnswer
  2. Obtain a serum tacrolimus trough concentration in 2 to 3 daysAnswer
  3. C
    Hold mycophenolate mofetil for the duration of antibiotic therapy
  4. D
    Monitor the activated partial thromboplastin time every 48 hours
  5. E
    Schedule an urgent ultrasound-guided percutaneous renal biopsy

Answer

The correct steps are to empirically reduce the daily dosage of tacrolimus and to obtain a serum tacrolimus trough concentration in 2 to 3 days.
Clarithromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, which is primarily responsible for the hepatic and intestinal metabolism of tacrolimus. When a strong CYP3A4 inhibitor is added to a patient stabilized on tacrolimus, the clearance of tacrolimus is drastically reduced, leading to supratherapeutic levels and a high risk of nephrotoxicity and neurotoxicity. Standard clinical management dictates an immediate empirical dose reduction of tacrolimus (often by 30% to 50%) along with early reassessment of the tacrolimus trough level (typically within 48 to 72 hours) to ensure the new dose maintains the patient within the narrow therapeutic index.

Step-by-Step Solution

1
Identify the critical drug-drug interaction between the newly prescribed medication and the patient's maintenance regimen.
Clarithromycin is identified as a strong CYP3A4 inhibitor, whereas tacrolimus is a major CYP3A4 substrate.
Recognizing this interaction is essential because adding a strong inhibitor will drastically increase the serum concentration of the substrate.
2
Determine the necessary pharmacological adjustment.
The daily dosage of tacrolimus must be empirically reduced at the time clarithromycin is initiated.
Preemptive dose reduction prevents acute tacrolimus toxicity, which can manifest as severe acute kidney injury, neurotoxicity, or new-onset diabetes.
3
Establish an ongoing monitoring plan.
A serum tacrolimus trough level should be scheduled for 2 to 3 days after initiating therapy.
Because the exact degree of CYP3A4 inhibition varies among individuals, early and serial therapeutic drug monitoring is required to titrate the tacrolimus dose back to the target therapeutic window.

Key Concept

CYP3A4 inhibitors (e.g., macrolide antibiotics like clarithromycin) significantly increase serum concentrations of calcineurin inhibitors (e.g., tacrolimus), requiring preemptive dose reduction and close therapeutic drug monitoring to prevent toxicity.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic